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The p53 tumour suppressor protein has a crucial role in cell-cycle
arrest and apoptosis. Previous reports show that the p53
messenger RNA is translated to produce an amino-terminal-
deleted isoform (DN-p53) from an internal initiation codon,
which acts as a dominant-negative inhibitor of full-length p53.
Here, we show that two internal ribosome entry sites (IRESs)
mediate the translation of both full-length and DN-p53 isoforms.
The IRES directing the translation of full-length p53 is in the
50-untranslated region of the mRNA, whereas the IRES mediating
the translation of DN-p53 extends into the protein-coding
region. The two IRESs show distinct cell-cycle phase-dependent
activity, with the IRES for full-length p53 being active at the
G2–M transition and the IRES for DN-p53 showing highest
activity at the G1–S transition. These results indicate a novel
translational control of p53 gene expression and activity.
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INTRODUCTION
The tumour suppressor protein p53 has a key role in maintaining
genomic integrity by controlling cell-cycle progression and cell
survival (Levine, 1997). Consistent with this view, about 50% of
human tumours carry mutations in the p53 gene (Hollstein et al,
1991). On exposure to stress stimuli, p53 is activated through
post-translational modifications, resulting in increased protein
stability and activity (Somasundaram & El-Deiry, 2000). The
increased levels of p53 protein may also result from the
enhancement of messenger RNA translation (Ko & Prives, 1996).
Previous studies have reported that a 40/47 kDa isoform of p53
(DN-p53), lacking the amino-terminal transactivation domain, is
generated by alternative translation initiation from an AUG codon
at position 40 of the p53 mRNA (Courtois et al, 2002; Yin et al,
2002). DN-p53, the expression of which was regulated in a
cell-cycle phase-dependent manner, inhibited the transcriptional
and growth-suppressive activities of full-length p53 in a dominant-
negative manner (Courtois et al, 2002). However, the precise
mechanism regulating the expression of the p53 isoforms remains
unknown. Internal ribosome entry site (IRES)-mediated translation,
where the ribosome is directly recruited to a site within the
50-untranslated region (50UTR) of the mRNA, is the most important
mode of alternative translation initiation of eukaryotic mRNAs
(Vagner et al, 2001). IRES-mediated translation has been demon-
strated in the picornavirus RNAs and in several cellular mRNAs
(IRES database, http://www.rangueil.inserm.fr/iresdatabase). Many
of these mRNAs encode proteins that are associated with the
control of cell proliferation and cell death (Holcik & Sonenberg,
2005). A common feature of many of the IRESs is their utilization of
non-canonical translation initiation factors referred to as IRES-
interacting trans-acting factors (ITAFs; Stoneley & Willis, 2004). The
spatial and temporal distribution of the ITAFs may be an important
mode of regulation of IRES activity and thereby of gene expression.
In this study, we show that the translation of full-length and
DN-p53 proteins is directed by two distinct IRESs that show
differential cell-cycle phase-dependent activity. These results
indicate a novel mode of regulation of p53 gene expression at
the level of translation initiation.
RESULTS
p53 50UTR mediates cap-independent translation
The MFOLD algorithm (Zuker, 2003) predicted the presence of
strong secondary structures in the 134 nt 50UTR and the 50 251 nt
region of the p53 mRNA (Fig 1A), with DG values of 57 and
92 kcal, respectively. The presence of these sequences upstream of
a green fluorescent protein (GFP) reporter gene reduced translation
by about 50% compared with a capped GFP RNA (compare black
bars in Fig 1B), but still allowed translation of the reporter gene
irrespective of the presence or absence of the cap. Interestingly,
addition of the cap analogue failed to inhibit the translation from
p53(þ 39)GFP RNA and only partially inhibited the translation
from the p53(1)GFP RNA, whereas it inhibited the translation from
capped GFP RNA (compare grey with black bars in Fig 1B). Similar
observations were made with a hepatitis C virus (HCV) 50UTR-GFP
RNA, which is known to be translated in a cap-independent manner
(Fig 1B). These results indicated that the p53(þ 39) and (1) 50UTRs
allowed cap-independent translation initiation.
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p53 50UTR sequences contain IRESs
To investigate whether the translation initiation by the p53 50UTR
sequences was by the internal entry of ribosomes, transient
transfections were carried out using bicistronic constructs, where
the upstream cistron Renilla luciferase (Rluc) is translated in a
cap-dependent manner, whereas the downstream firefly luciferase
(Fluc) will be translated if the intercistronic sequence contains
an IRES (Fig 2A). Bicistronic plasmids pRp53(þ 39)F and
pRp53(1)F, transfected into HeLa cells, showed around
11- and 5-fold higher Fluc activity, respectively, than that of the
control bicistronic DNA pRnullF, which had an unrelated
sequence in the intercistronic space (Fig 2B(i)). These results
indicated the presence of IRES elements in both p53(þ 39) and
(1) sequences. To rule out the ribosomal read-through of the
intercistronic sequences, they were cloned in the plasmid pRDEF,
downstream of a stable RNA structure derived from the
encephalomyocarditis virus (EMCV) IRES that inhibits ribosomal
read-through (Johannes et al, 1999). These bicistronic DNAs,
pRDEp53(þ 39)F and pRDEp53(1)F, produced 13- and 12-fold
higher Fluc activity, respectively, than that from the control vector
pRDEF (Fig 2B(ii)). Similar results were obtained from the p53-null
human lung carcinoma cell line H1299 (Fig 2C(i,ii)). Ribosomal
read-through of the second cistron was further ruled out by
inserting the 440 nt EMCV sequence upstream of the Rluc gene in
the bicistronic constructs. This resulted in a strong reduction in the
translation of Rluc (Fig 2D, black bars), but no significant change
in Fluc expression (Fig 2D, grey bars). Together, these results
indicated that the translation from the p53(þ 39) and (1) 50UTRs
was IRES mediated and not due to ribosomal read-through.
The efficiency of the p53(þ 39) IRES in HeLa cells was similar
to that of the heavy chain immunoglobulin binding protein (BiP)
IRES, a known cellular IRES. The efficiency of the (1) IRES was
similar to that of the hepatitis A virus IRES (supplementary Fig 1A
online). We also investigated whether the translation mediated by
the p53(þ 39) IRES was independent of that mediated by the
p53(1) IRES. Specifically, we wanted to rule out the possibility
that the translation mediated by the p53(þ 39) sequence was due
to ribosome binding to the (1) IRES and initiation from the þ 1
initiation codon. This was necessitated by the fact that the ATG
of the Fluc gene was in-frame with the þ 1 ATG of the p53(þ 39)
sequence in the bicistronic construct. However, transfection of
a p53(þ 39) bicistronic construct with the þ 1 ATG mutated to
AAG did not show any significant change in Fluc activity com-
pared with the wild-type p53(þ 39) bicistronic DNA (supplemen-
tary Fig 1B online). This indicated that the translation mediated by
p53(þ 39) IRES was independent of that mediated by the (1)
IRES, and supported earlier observations that the mutation of the
þ 1 ATG did not abrogate the translation of DN-p53.
p53 50UTR does not have splice sites or cryptic promoters
To rule out the possibility that the Fluc activity from the p53(þ 39)
bicistronic DNA was due to the presence of splice sites or cryptic
promoters, which would generate monocistronic Fluc RNAs
in vivo, RNA analyses were carried out with the RNA extracted
from HeLa cells transfected with p53 bicistronic DNAs. Reverse
transcription–PCR (RT–PCR) and northern blot analysis showed
the presence of full-length bicistronic RNA and no smaller RNA
species, demonstrating that the Rluc and Fluc cistrons were part of
a single transcript (Fig 3A,B).
However, there is a possibility that small amounts of
monocistronic transcripts of the second cistron may be generated,
which are not detectable by the RNA analyses but may contribute
to Fluc activity. To rule out this possibility, a bicistronic plasmid
pBS-Rp53(þ 39)F, lacking a eukaryotic promoter but containing
a T7 promoter, was transfected into HeLa cells. This plasmid did
not produce any Fluc or Rluc activity (Fig 3C), demonstrating the
absence of a cryptic promoter within the p53 50UTR sequence that
could drive the transcription of Fluc RNA. Only when the cells
were infected with a vaccinia virus expressing T7 RNA poly-
merase (VTF7-3; Fuerst et al, 1986) was high expression of both
Fluc and Rluc observed (Fig 3C). The negative control pBSRnullF
did not show any luciferase activity when transfected alone, but
showed only high Rluc activity when the cells were infected with
VTF7-3. Finally, transfection of HeLa cells with the capped
bicistronic RNAs showed a Fluc/Rluc ratio significantly higher
than that from an empty bicistronic RNA (Fig 3D). Together, these
results demonstrated that the expression of the downstream cistron
from p53 bicistronic constructs is not due to splicing or cryptic
promoter activity.
Cell-cycle phase-dependent regulation of p53 IRES
The expression of DN-p53 was shown to vary during cell-cycle
progression, with the maximum expression being observed during
the G1–S transition, which was accompanied by a transient
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Fig 1 | p53 50-untranslated regions mediate cap-independent translation.
(A) Nucleotide sequence of p53 50-untranslated region (50UTR) and part
of the protein-coding region. The 134 nt canonical 50UTR is underlined
by a solid line, whereas the 251 nt 50UTR for DN-p53 is underlined
by a dotted line. (B) In vitro translation of capped and uncapped
monocistronic RNAs in the presence or absence of exogenously
added cap analogue. The band intensities were quantified and are
represented graphically.
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decrease of full-length p53. We investigated the activities of the
IRESs mediating translation of DN-p53 and full-length p53 at
different phases of the cell cycle. HeLa cells were transfected with
pRp53(þ 39)F or pRp53(1)F bicistronic plasmids and then
blocked at G2–M transition by nocodazole treatment. On
releasing the cells and assaying for luciferase activity at different
time points, the p53(þ 39) IRES showed maximum activity at the
24 h time point (Fig 4B). Flow cytometric analysis showed that this
coincided with the highest number of cells being in the S phase
(Fig 4A). This suggested that the p53(þ 39) IRES activity was
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Fig 2 | p53 50-untranslated region sequences mediate internal ribosome entry site-dependent translation. (A) Schematic representation of bicistronic
plasmids used in transient transfections. (B(i)) Transfection of bicistronic plasmids pRnullF, pRp53(þ 39)F and pRp53(1)F containing a 264 nt
unrelated sequence, p53 50UTR (þ 39) and (1) sequences, respectively, in the intercistronic space into HeLa cells. (ii) Transfection of bicistronic
plasmids containing p53 50UTR (þ 39) and (1) downstream of the DEMCV sequence. The control bicistronic plasmid pRDEF contained only the
DEMCV sequence. Transfection efficiencies were normalized by co-transfecting with a b-galactosidase plasmid. The luciferase activities for Fluc and
Rluc are shown separately as fold increase compared with that from control, taken as 1. (C(i,ii)) Transfection of the same set of bicistronic plasmids
into H1299 cells. The data are represented as in (B). (D) Transfection of bicistronic plasmids containing p53 50UTR (þ 39) or (1) sequences in the
intercistronic place and the DEMCV sequence upstream of Rluc into HeLa cells. The Fluc and Rluc activities from the DEMCV-containing plasmids
are shown as fold increase or decrease with respect to the corresponding controls, taken as 100.
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maximum during the progression into S phase, and is supported by
the earlier observation that the level of DN-p53 protein, which is
translated by this IRES, is maximum at this phase.
On the other hand, the maximum activity of the p53(1) IRES
was found to be at the G2–M transition (0 h) and decreased sub-
sequently (Fig 4C). Interestingly, it again increased at the 42 h time
point, which coincided with the increase in number of cells in the
G2–M phase. These observations suggested that the p53(1) IRES,
which evidently controls the translation of full-length p53, is most
active during the G2–M transition. In support of these observa-
tions, when we blocked the transfected cells at the end of the G1
phase by double thymidine treatment and carried out luciferase
assays at subsequent time points, the p53(þ 39) IRES and the
p53(1) IRES were again found to be maximally active at the G1–
S and G2–M transitions, respectively (supplementary Fig 2 online).
DISCUSSION
IRES-mediated translation is an important mode of alternative
translation initiation of cellular mRNAs and has been implicated
in the regulation of gene expression under different physiological
conditions (Hellen & Sarnow, 2001). p53 has a crucial role in cell-
cycle progression and has both G1/S and G2/M checkpoint
functions. Earlier results have suggested that DN-p53, which is
highly expressed at the onset of S phase, might facilitate G1–S
transition by inhibiting wild-type p53 activity (Courtois et al,
2002). Our study showed that the IRES, mediating the translation
of DN-p53, is most active at the G1–S transition. The increase
in IRES activity at this stage would result in a higher level of
expression of DN-p53, which is expected to exert a significant
negative effect on full-length p53 activity, especially because the
DN-p53 isoform is resistant to Mdm2-mediated degradation (Yin
et al, 2002). This would counteract the cell-cycle checkpoint
activity of p53 in normal cells and allow the progression into the
S phase (supplementary Fig 3 online).
On the other hand, the IRES mediating the translation of full-
length p53 showed the highest activity at the G2–M transition.
Cellular cap-dependent translation is known to be downregulated
during the G2–M transition. IRESs mediating the translation of
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several mRNAs show high activity during this phase of the cell
cycle (Stoneley & Willis, 2004), suggesting that IRES-mediated
translation provides an alternative mode of protein synthesis at this
stage. As p53 activity is required for the G2/M checkpoint (Bunz
et al, 1998), the increased activity of this IRES at the G2–M
transition may be responsible for maintaining the synthesis of
basal levels of p53 protein. As the efficiency of the IRES mediating
the translation of full-length p53 is low, the small amounts of full-
length p53 protein would be efficiently degraded by the Mdm-2-
mediated pathway, allowing the progression of cells into the next
phase of the cell cycle. Our observations suggest a very intricate
regulation of p53 gene expression by the differential activities of
the two IRESs (supplementary Fig 3 online). Other cell-cycle-
regulated IRESs, such as that of the PITSLRE protein kinase, have
been reported previously (Cornelis et al, 2000). The presence of
two independent IRESs, differentially regulating vascular endo
thelial growth factor expression, has been reported before in the
vascular endothelial growth factor mRNA (Huez et al, 1998). Also,
IRESs present within coding sequences and mediating the trans-
lation of truncated versions of proteins have been reported in the
case of p58PITSLRE (Cornelis et al, 2000) and oestrogen receptor
(Barraille et al, 1999) mRNAs. This study, for the first time,
suggests the presence of two IRESs mediating the translation
of two different isoforms of the same protein. However, we cannot
rule out the possibility that only one IRES is present in the
p53 mRNA, which alternatively allows translation initiation
from two different downstream initiation codons, and the use of
either of these initiation codons is regulated in a cell-cycle-
dependent manner.
The interaction of different ITAFs with the cellular IRESs
is an important mechanism of regulation of translation initiation.
Several proteins, including p53 itself, have been reported to
interact with the 50UTR of the p53 mRNA. p53 interaction with the
50UTR was found to inhibit the translation of the p53 mRNA,
thereby exerting a negative autoregulatory control (Mosner et al,
1995). Interestingly, it was also shown that although p53 mRNA
production peaks at the G1–S phase of the cell cycle, the protein
level is maximal at mid-S. This suggests that the relative ratios of
p53 and DN-p53 may be crucial in regulating the translation of
p53. High levels of DN-p53, produced at the G1–S transition by
the activity of the (þ 39) IRES, might prevent the binding of full-
length p53 to the 50UTR and thereby allow the production of full-
length p53 at mid-S phase. Following synthesis of a sufficient level
of full-length p53, it would interact with the 50UTR of its own
mRNA and inhibit its translation, creating a negative feedback
loop and allowing the cells to enter the G2–M phase of the cell
cycle (supplementary Fig 3 online). This model suggests an
intricate regulation of p53 expression by RNA–protein inter-
actions, which is required for allowing the normal progression of
the cell cycle and for eliciting cell-cycle checkpoint controls
under conditions such as DNA damage. Recently, two other
proteins, ribosomal protein L26a and nucleolin, have been shown
to interact with the p53 50UTR and modulate its translation (Takagi
et al, 2005). Interestingly, nucleolin and other ribosomal proteins
have been shown to interact with viral IRESs (Fukushi et al, 2001;
Izumi et al, 2001). Therefore, the interaction of nucleolin and
RPL26a with the p53 mRNA 50UTR might regulate the activities of
the p53 IRESs. Future studies on the role of these and other p53
IRES-interacting proteins would provide further insights into the
regulation of p53 gene expression under various physiological and
stress conditions.
METHODS
Plasmid constructs. The complementary DNAs corresponding to
the 50 251 and 134 nt region of p53 mRNA were isolated from the
blood of a healthy individual and cloned and sequenced
(GenBank accession number AY627884). The 251 and 134 nt
DNAs were cloned into pCDNA3 vector (Invitrogen, Carlsbad,
CA, USA) upstream of GFP to generate monocistronic constructs.
The HCV-IRES–GFP construct had the HCV IRES upstream of GFP.
All bicistronic constructs had the respective 50UTR sequences
cloned between Rluc and Fluc genes, in pCDNA3.1, which does
not contain a chimeric intron. p53 50UTR sequences were also
cloned downstream of the inactive DEMCV IRES sequence in the
intercistronic region of the plasmid pRDDEF (Johannes et al,
1999). The DEMCV sequence was also cloned upstream of Rluc
gene in the bicistronic plasmids. The ATG codon at position þ 1
in p53 50UTR (þ 39) was mutated to AAG and cloned into a
bicistronic construct. The eukaryotic promoter-less bicistronic
construct pBS-Rp53(þ 39)F had the bicistronic cassette containing
the p53(þ 39) 50UTR cloned into the vector pBluescript-KS
(Stratagene, La Jolla, CA, USA) under the T7 promoter.
In vitro transcription. Monocistronic plasmids were linearized
downstream of GFP and transcribed using T7 RNA polymerase in
the presence/absence of RNA Cap Analog (Promega, Madison,
WI, USA). Bicistronic plasmids were linearized downstream of
Fluc and transcribed to generate capped RNAs.
In vitro translation. In vitro translation was carried out in rabbit
reticulocyte lysate medium (Promega) using [35S]methionine
(Perkin-Elmer Life Sciences, Singapore) and the products were
resolved on SDS–polyacrylamide gel electrophoresis (as described
previously, Ray & Das, 2004). A 2 mM RNA Cap Analog
(Promega) or an equivalent amount of GTP was added to
reactions, as indicated.
Reverse transcription–PCR analysis. Total RNA isolated by Trizol
reagent (Sigma) from untransfected and transfected HeLa cells was
pretreated with DNase I and analysed by RT–PCR using two sets
of primers: P1(forward)/P2(reverse), corresponding to the 30
region of Rluc gene and 30 region of Fluc gene, respectively,
and P3(forward)/P4(reverse), corresponding to the 50 region of
Rluc and 50 region of Fluc, respectively.
Northern blotting. Total RNAs from HeLa cells, transfected with
p53(þ 39), p53(1) and CVB3-IRES bicistronic plasmids, and
Control Fluc RNA (Promega) were resolved on 1% agarose gel,
blotted on nylon membrane and hybridized with a 32P-labelled
riboprobe corresponding to the Fluc gene.
Cell transfection and synchronization. HeLa S3 and human lung
carcinoma H1299 cells were maintained in DMEM (Invitrogen)
with 10% fetal bovine serum. Cells were transfected with various
bicistronic plasmids or capped bicistronic RNAs using Tfx 20
reagent (Promega). Luciferase assay was carried out in
DNA-transfected cells 24 h after transfection and in RNA-
transfected cells 6 h after transfection. In experiments using
eukaryotic promoter-less bicistronic constructs, cells were
infected with a vaccinia virus expressing T7 RNA polymerase
(VTF7.3) before transfection with bicistronic plasmids.
At 24 h after transfection with bicistronic plasmids, cells were
synchronized either at G2/M phase by nocodazole (500 ng/ml) or
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at S phase by double thymidine treatment (2 mM). Subsequently,
the blocked cells were released by washing with PBS and
collected at various time points for either the luciferase assay or
flow cytometry. Flow cytometry was carried out after staining
DNA with propidium iodide (Sigma-Aldrich, St Louis, MO, USA).
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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